Eaton Vance Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.33M | Hold |
20,413
| – | – | ﹤0.01% | 1163 |
|
|
2022
Q2 | $1.24M | Sell |
20,413
-1,180
| -5% | -$71.7K | ﹤0.01% | 1209 |
|
|
2022
Q1 | $1.36M | Sell |
21,593
-70
| -0.3% | -$4.39K | ﹤0.01% | 1295 |
|
|
2021
Q4 | $1.64M | Buy |
21,663
+70
| +0.3% | +$5.31K | ﹤0.01% | 1066 |
|
|
2021
Q3 | $2.29M | Buy |
21,593
+180
| +0.8% | +$19K | ﹤0.01% | 904 |
|
|
2021
Q2 | $3.47M | Buy |
21,413
+1,000
| +5% | +$162K | ﹤0.01% | 876 |
|
|
2021
Q1 | $2.49M | Hold |
20,413
| – | – | ﹤0.01% | 924 |
|
|
2020
Q4 | $3.13M | Hold |
20,413
| – | – | ﹤0.01% | 828 |
|
|
2020
Q3 | $1.71M | Hold |
20,413
| – | – | ﹤0.01% | 871 |
|
|
2020
Q2 | $1.5M | Hold |
20,413
| – | – | ﹤0.01% | 874 |
|
|
2020
Q1 | $866K | Hold |
20,413
| – | – | ﹤0.01% | 945 |
|
|
2019
Q4 | $1.24M | Hold |
20,413
| – | – | ﹤0.01% | 926 |
|
|
2019
Q3 | $837K | Hold |
20,413
| – | – | ﹤0.01% | 1013 |
|
|
2019
Q2 | $961K | Hold |
20,413
| – | – | ﹤0.01% | 964 |
|
|
2019
Q1 | $729K | Hold |
20,413
| – | – | ﹤0.01% | 991 |
|
|
2018
Q4 | $583K | Hold |
20,413
| – | – | ﹤0.01% | 969 |
|
|
2018
Q3 | $905K | Hold |
20,413
| – | – | ﹤0.01% | 935 |
|
|
2018
Q2 | $1.2M | Buy |
+20,413
| New | +$1.2M | ﹤0.01% | 848 |
|